uniQure receives Priority Review for AMT-130 BLA
uniQure reports 2026 Q3 results; FDA granted Priority Review for AMT-130 with a PDUFA date of May 1, 2027; company expects cash runway into 2030.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed